Evidence map›Paper›PMID 27539393›Full record

ArticleBJU international2017

Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.

Andrew S McDaniel, Roberta Ferraldeschi, Rachel Krupa, Mark Landers, Ryon Graf, Jessica Louw, Adam Jendrisak, Natalee Bales, Dena Marrinucci, Zafeiris Zafeiriou and 9 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJU international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 65 citations in OpenAlex.

  1. A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Andrew S McDanielDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Roberta FerraldeschiThe Institute of Cancer Research, London, UK.
Rachel KrupaEpic Sciences, San Diego, CA, USA.
Mark LandersEpic Sciences, San Diego, CA, USA.
Ryon GrafEpic Sciences, San Diego, CA, USA.
Jessica LouwEpic Sciences, San Diego, CA, USA.
Adam JendrisakEpic Sciences, San Diego, CA, USA.
Natalee BalesEpic Sciences, San Diego, CA, USA.
Dena MarrinucciEpic Sciences, San Diego, CA, USA.
Zafeiris ZafeiriouThe Institute of Cancer Research, London, UK.
Penelope FlohrThe Institute of Cancer Research, London, UK.
Spyridon SiderisThe Institute of Cancer Research, London, UK.
Mateus CrespoThe Institute of Cancer Research, London, UK.
Ines FigueiredoThe Institute of Cancer Research, London, UK.
Joaquin MateoThe Institute of Cancer Research, London, UK.
Johann S de BonoThe Institute of Cancer Research, London, UK.
Ryan DittamoreEpic Sciences, San Diego, CA, USA.
Scott A TomlinsDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.
Gerhardt AttardThe Institute of Cancer Research, London, UK.
Epic Sciences (United States) · USInstitute of Cancer Research · GBRoyal Marsden NHS Foundation Trust · GBMichigan Center for Translational Pathology · USUniversity of Michigan–Ann Arbor · US

Funding

Exploiting drivers of androgen receptor signaling negative prostate cancer for prR01CA183857 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TOMLINS, SCOTT A · 2014 to 2018
$1.6M
Cancer Research UK 13239Cancer Research UK 22744Medical Research Council G0601308NCI NIH HHS R01 CA183857
6 · The paper itself

Abstract

objectivesTo use a non-biased assay for circulating tumour cells (CTCs) in patients with prostate cancer (PCa) in order to identify non-traditional CTC phenotypes potentially excluded by conventional detection methods that are reliant on antigen- and/or size-based enrichment. PATIENTS AND

methodsA total of 41 patients with metastatic castration-resistant PCa (mCRPC) and 20 healthy volunteers were analysed on the Epic CTC platform, via high-throughput imaging of DAPI expression and CD45/cytokeratin (CK) immunofluorescence (IF) on all circulating nucleated cells plated on glass slides. To confirm the PCa origin of CTCs, IF was used for androgen receptor (AR) expression and fluorescence in situ hybridization was used for PTEN and ERG assessment.

resultsTraditional CTCs (CD45

conclusionsHeterogeneous non-traditional CTC populations are frequent in mCRPC and may provide additional prognostic or predictive information.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorDisease ProgressionHumansIn Situ Hybridization, FluorescenceMaleMiddle AgedNeoplasm MetastasisNeoplastic Cells, CirculatingPhenotypeProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantPTEN PhosphohydrolaseReceptors, AndrogenBiomarkers, TumorProstate-Specific AntigenPTEN PhosphohydrolasePTEN protein, humanReceptors, Androgencirculating tumour cellsERGliquid biopsymetastatic castration-resistant prostate cancerPTEN

Identifiers

PMID27539393
PMCPMC5316381
OpenAlexW2517387251

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.